Last reviewed · How we verify
NCT05968235
Correlation of Glucose and Lipid Metabolism Levels With Vitiligo
trial testing Collecting blood samples in Metabolism Disorder, Glucose in 963 participants. Completed in 25 March 2023.
25 March 2022
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 963 |
| Start date | 1 February 2020 |
| Primary completion | 25 March 2022 |
| Estimated completion | 25 March 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Collecting blood samples
Conditions studied
- Metabolism Disorder, Glucose — all drugs for Metabolism Disorder, Glucose →
- Metabolism Disorder, Lipid — all drugs for Metabolism Disorder, Lipid →
- Vitiligo — all drugs for Vitiligo →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 60, any sex, with Metabolism Disorder, Glucose or Metabolism Disorder, Lipid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to compare serum glucose and lipid metabolism levels between health volunteers and vitiligo patients. The main question it aims to answer is whether vitiligo is related to glucose and lipid metabolism disorders. Participants will complete a vitiligo questionnaire and test serum levels of indicators related to glucose and lipid metabolism. Researchers will compare vitiligo patients with healthy volunteers to see if there is a correlation between vitiligo and disorders of glucose and lipid metabolism.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dysregulated Intracellular Signaling in the Pathogenesis of Vitiligo: An Update on Emerging Therapeutic Strategies.
Marrapodi R, Marini A, Bellei B. · · 2025 · PMID 41007740 · DOI 10.3390/biomedicines13092177
Verify or expand the search:
- PubMed search for NCT05968235
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05968235 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05968235.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing